A radioimmunoconjugate comprised of the humanized monoclonal antibody HuPAM4, directed against the pancreatic cancer antigen MUC1, that is conjugated to the chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) and radiolabeled with the beta-emitting radioisotope Yttrium Y90. Yttrium Y 90 DOTA monoclonal antibody HuPAM4 binds to tumor cells expressing MUC1 antigen, selectively delivering a cytotoxic dose of beta radiation.

A substance being studied in the treatment of advanced pancreatic cancer. HuPAM4 is a monoclonal antibody that can locate and bind to pancreatic cancer cells. It is linked to a radioactive substance called yttrium Y90, which may help kill cancer cells. Yttrium Y 90 DOTA monoclonal antibody HuPAM4 is a type of radioimmunoconjugate.